Results 11 to 20 of about 2,762 (187)

The epigenetic mechanisms of adaption to the hot and humid climate in Hu sheep (Ovis aries) [PDF]

Physiological Reports
Hu sheep is characterized by its excellent fecundity and high adaptability to various ecological environments. To reveal the molecular basis involved in Hu sheep, we first examined the 10 index of neuroendocrine and metabolism in blood in Hu sheep during
Hangxing Ren, Jing Jiang, Jie Li, Xiaoyan Sun, Cancan Chen, Liangjia Liu, Shipeng Lv, Minghao Qu, Yuxue Fan, Peng Zhou, Gaofu Wang   +10 more
doaj   +3 more sources

ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein) [PDF]

Circulation, 2018
Background: Pharmacogenomic studies have shown that ADCY9 genotype determines the effects of the CETP (cholesteryl ester transfer protein) inhibitor dalcetrapib on cardiovascular events and atherosclerosis imaging.
Y. Rautureau, Vanessa Deschambault, Marie‐Eve Higgins, D. Rivas, M. Mecteau, P. Geoffroy, Géraldine Miquel, Kurunradeth Uy, Rocio Sanchez, Véronique Lavoie, G. Brand, Audrey Nault, P. Williams, M. Suarez, Nolwenn Merlet, Line Lapointe, N. Duquette, Marc‐Antoine Gillis, Samaneh Samami, G. Mayer, P. Pouliot, Adeline Raignault, Foued Maafi, Mathieu R. Brodeur, S. Lévesque, M. Guertin, M. Dubé, É. Thorin, D. Rhainds, É. Rhéaume, J. Tardif   +30 more
semanticscholar   +4 more sources

The ADCY9 genetic variants are associated with glioma susceptibility and patient prognosis.

Genomics, 2020
Genetic factor is a risk factor in glioma occurrence. This study was designed to detect the effect of ADCY9 polymorphisms on glioma risk and prognosis.We performed a case-control study of 1080 participants (584 cases and 496 controls) to assess the relationship of ADCY9 polymorphisms with the risk and prognosis of glioma among the Chinses Han ...
Gang Zhang, M. Xi, Yuqian Li, Liang Wang, L. Gao, Luying Zhang, Zhangkai Yang, Hangyu Shi   +7 more
semanticscholar   +4 more sources

CETP inhibition and ADCY9 genotype: evidence of a qualitative pharmacogenetic interaction in cardiovascular disease? [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2018
Background CETP inhibitors raise circulating concentrations of HDL-cholesterol, and potent inhibitors also lower non-HDL-cholesterol and risk of vascular disease.
M. Holmes, G. Davey Smith
semanticscholar   +3 more sources

ADCY9 wt Allele [PDF]

Definitions, 2020
National Cancer Institute
semanticscholar   +3 more sources

[Association of the ADCY9 gene and gene-environmental interaction with the susceptibility to childhood bronchial asthma]. [PDF]

Zhongguo Dang Dai Er Ke Za Zhi, 2022
Jia JJ, Wei B, Li LX, Ren MY, Zhang SN, Liu J, Zhang YX.   +6 more
europepmc   +4 more sources

Adenylate cyclase 9 expression level is associated with hormone receptor-positive breast cancer and predicts patient prognosis. [PDF]

Nagoya J Med Sci
Adenylate cyclase family members have recently received attention as novel therapeutic targets. However, the significance of adenylate cyclase 9 (ADCY9) in breast cancer has not been elucidated.
Sugino K, Shibata M, Adachi Y, Soeda I, Ichikawa T, Inaishi T, Kanaya E, Kanda M, Hayashi M, Masuda N.   +9 more
europepmc   +4 more sources

Cloning, chromosomal mapping, and regulatory properties of the human type 9 adenylyl cyclase (ADCY9).

Genomics, 1998
The type 9 adenylyl cyclase (AC9) is a widely distributed adenylyl cyclase that was originally cloned from a mouse cDNA library. Here we report the cloning, chromosomal mapping, and regulatory properties of human AC9 (HGMW-approved symbol ADCY9). Although the human AC9 sequence shows 86% homology with mouse AC9, divergence at the C2a/C2b junction ...
B. Hacker, J. Tomlinson, G. Wayman, R. Sultana, G. Chan, E. Villacres, C. Disteche, D. Storm   +7 more
semanticscholar   +4 more sources

Abstract 624: Interactions Between Adenylate Cyclase Type 9 (ADCY9) and Cholesteryl Ester Transfer Protein (CETP) in Atherosclerosis [PDF]

, 2018
AbstractBackgroundCETP inhibitors raise circulating concentrations of HDL-cholesterol, and potent inhibitors also lower non-HDL-cholesterol and risk of vascular disease. Previous genome-wide pharmacogenetic analysis of a phase III randomized controlled trial (RCT) of the CETP inhibitor, dalcetrapib, found variants in ADCY9 to associate with response to
Y. Rautureau, Vanessa Deschambault, Marie‐Eve Higgins, D. Rivas, M. Mecteau, P. Geoffroy, Géraldine Miquel, Kurunradeth Uy, Rocio Sanchez, Audrey Nault, P. Williams, M. Suarez, G. Brand, Line Lapointe, N. Duquette, Marc‐Antoine Gillis, Samaneh Samami, G. Mayer, P. Pouliot, Adeline Raignault, Foued Maafi, Mathieu R. Brodeur, S. Lévesque, M. Guertin, M. Dubé, É. Thorin, D. Rhainds, É. Rhéaume, J. Tardif   +28 more
semanticscholar   +3 more sources

Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy

Journal of Clinical Pharmacy and Therapeutics, 2011
What is known and objective:  Inhaled combination therapy composing of long‐acting β2‐agonist and corticosteroid has been widely applied in the management of asthma, but observed treatment responses vary.
Seung-Hyun Kim, Y. Ye, H. Lee, H. Sin, Hae-Sim Park   +4 more
semanticscholar   +5 more sources